Table 3. ATC Classification of Cancer Drugs in Thailand, Hong Kong, England, and Italy .
| ATC classification | Thailand | Hong Kong | England | Italy | ||||||||||||||||
| Reimbursable Under Regular Benefits Package | Reimbursable Under Special Programs | Not Reimbursable | Not Registered | Total | Reimbursable Under Regular Benefits Package | Reimbursable Under the Dedicated Drugs Fund | Not Reimbursable | Not Registered | Total | Reimbursable Under Regular Benefits Package | Reimbursable Under the Dedicated Drugs Fund | Not Reimbursable | Not Registered | Total | Reimbursable Under Regular Benefits Package | Reimbursable Under the Dedicated Drugs Fund | Not Reimbursable | Not Registered | Total | |
| Alkylating agents | 8 | 0 | 2 | 9 | 19 | 11 | 1 | 0 | 7 | 19 | 11 | 2 | 0 | 6 | 19 | 12 | 0 | 7 | 0 | 19 |
| Alkylating agents; platinum coordination complexes | 3 | 0 | 0 | 0 | 3 | 3 | 0 | 0 | 0 | 3 | 3 | 0 | 0 | 0 | 3 | 3 | 0 | 0 | 0 | 3 |
| Antibiotics, cytotoxic | 6 | 0 | 2 | 5 | 13 | 8 | 1 | 1 | 3 | 13 | 6 | 1 | 0 | 6 | 13 | 8 | 0 | 5 | 0 | 13 |
| Antimetabolites; antifolates | 1 | 0 | 2 | 2 | 5 | 2 | 0 | 0 | 3 | 5 | 3 | 0 | 0 | 2 | 5 | 3 | 0 | 2 | 0 | 5 |
| Antimetabolites; purine analogues | 3 | 0 | 2 | 2 | 7 | 5 | 0 | 0 | 2 | 7 | 3 | 2 | 0 | 2 | 7 | 7 | 0 | 0 | 0 | 7 |
| Antimetabolites; pyrimidine analogues | 4 | 0 | 3 | 3 | 10 | 4 | 1 | 1 | 4 | 10 | 7 | 1 | 1 | 1 | 10 | 7 | 0 | 3 | 0 | 10 |
| Histone deacetylase inhibitors | 0 | 0 | 0 | 4 | 4 | 0 | 0 | 0 | 4 | 4 | 0 | 1 | 0 | 3 | 4 | 0 | 0 | 4 | 0 | 4 |
| Hormonal agents; antiandrogens | 2 | 2 | 2 | 2 | 8 | 3 | 2 | 1 | 2 | 8 | 2 | 3 | 1 | 2 | 8 | 7 | 0 | 1 | 0 | 8 |
| Hormonal agents; antiestrogens (including aromatase inhibitors) | 2 | 0 | 3 | 2 | 7 | 4 | 0 | 1 | 2 | 7 | 4 | 0 | 2 | 1 | 7 | 7 | 0 | 0 | 0 | 7 |
| Hormonal agents; gonadotropin releasing hormone analogues | 4 | 0 | 2 | 4 | 10 | 6 | 0 | 0 | 4 | 10 | 0 | 1 | 1 | 8 | 10 | 7 | 0 | 3 | 0 | 10 |
| Hormonal agents; peptide hormones | 1 | 0 | 1 | 0 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 2 |
| Monoclonal antibodies | 4 | 2 | 16 | 22 | 44 | 5 | 13 | 3 | 23 | 44 | 7 | 23 | 8 | 6 | 44 | 22 | 8 | 14 | 0 | 44 |
| Protein kinase inhibitors | 5 | 10 | 27 | 32 | 74 | 4 | 26 | 6 | 38 | 74 | 11 | 42 | 11 | 10 | 74 | 41 | 8 | 25 | 0 | 74 |
| Topoisomerase inhibitors | 3 | 0 | 0 | 3 | 6 | 2 | 0 | 1 | 3 | 6 | 3 | 0 | 0 | 3 | 6 | 4 | 0 | 2 | 0 | 6 |
| Taxanes | 2 | 0 | 2 | 0 | 4 | 2 | 0 | 1 | 1 | 4 | 1 | 2 | 0 | 1 | 4 | 3 | 0 | 1 | 0 | 4 |
| Vinca alkaloids | 3 | 0 | 1 | 2 | 6 | 3 | 0 | 0 | 3 | 6 | 3 | 0 | 0 | 3 | 6 | 5 | 0 | 1 | 0 | 6 |
| Biologic response modifiers | 0 | 0 | 1 | 3 | 4 | 1 | 0 | 1 | 2 | 4 | 2 | 0 | 1 | 1 | 4 | 2 | 0 | 2 | 0 | 4 |
| Monoclonal antibodies and topoisomerase inhibitors | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 2 | 2 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 2 | 0 | 2 |
| Monoclonal antibodies and cytotoxic agent | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| Combination | 1 | 0 | 0 | 6 | 7 | 1 | 0 | 0 | 6 | 7 | 0 | 4 | 0 | 3 | 7 | 2 | 0 | 5 | 0 | 7 |
| Miscellaneous | 7 | 1 | 9 | 16 | 33 | 11 | 4 | 1 | 17 | 33 | 6 | 11 | 7 | 9 | 33 | 20 | 2 | 11 | 0 | 33 |
| Total | 59 | 15a | 76 | 119 | 269 | 77 | 49b | 17 | 126 | 269 | 74 | 95 | 33 | 67 | 269 | 163 | 18 | 88 | 0 | 269 |
Abbreviation: ATC, Anatomical Therapeutic Chemical.
a Six cancer drugs in Thailand including bevacizumab, dasatinib, imatinib, nilotinib, rituximab, and trastuzumab are reimbursed under regular benefits package of Thailand with additional indications reimbursed under the OCPA.
b Seven cancer drugs in Hong Kong including cetuximab, dasatinib, everolimus, imatinib, interferon alfa, rituximab, and temozolomide are reimbursed under regulars benefit package of Hong Kong with additional indications reimbursed under SF and CCF.